Vertex Pharmaceuticals Incorporated
VRTX
$489.10
$3.210.66%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -535.60M | -479.80M | -489.90M | 4.02B | 3.62B |
| Total Depreciation and Amortization | 182.00M | 207.90M | 196.80M | 184.20M | 169.50M |
| Total Amortization of Deferred Charges | 25.20M | 11.80M | 11.80M | 11.80M | 11.80M |
| Total Other Non-Cash Items | 350.60M | 211.00M | 99.40M | 3.90M | 2.10M |
| Change in Net Operating Assets | -514.80M | -793.50M | -762.10M | -275.30M | -265.70M |
| Cash from Operations | -492.60M | -842.60M | -944.00M | 3.94B | 3.54B |
| Capital Expenditure | -297.70M | -263.20M | -236.10M | -226.70M | -200.40M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.47B | -3.57B | -3.37B | -3.22B | -2.94B |
| Cash from Investing | -3.77B | -3.83B | -3.60B | -3.44B | -3.14B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -33.60M | -44.30M | -50.20M | -47.50M | -44.90M |
| Issuance of Common Stock | 114.60M | 126.70M | 133.70M | 137.30M | 134.60M |
| Repurchase of Common Stock | -1.58B | -1.31B | -1.09B | -719.00M | -653.70M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 6.20M | 3.80M | 4.00M | 4.20M | 1.80M |
| Cash from Financing | -1.49B | -1.22B | -1.00B | -625.00M | -562.20M |
| Foreign Exchange rate Adjustments | -42.60M | 32.10M | -13.20M | -700.00K | 26.90M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.80B | -5.87B | -5.56B | -126.20M | -139.70M |